Psychedelic biotech ATAI hopes to expand portfolio through research partnership with Mass General
Psychedelics have made a comeback for mental health research, with companies like startup biotech ATAI Life Sciences raising millions and earning the backing of prominent investors like Peter Thiel, but there’s a hole at the heart of the resurgence: Researchers still don’t fully understand how they work.
A new partnership between ATAI and world-renowned Mass General Hospital hopes to change that.
ATAI is the first partner in Mass General’s new Center for Neuroscience of Psychedelics, which seeks to advance novel mental health treatments through studying the mechanisms that underlie the therapeutic effects of psychedelic agents. The Berlin-based company, founded in 2018, focuses on developing psychedelic and non-psychedelic compounds for a variety of mental health needs.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters